Rechallenge with dabrafenib plus trametinib in anaplastic thyroid cancer: A case report and review of literature

达布拉芬尼 曲美替尼 医学 甲状腺间变性癌 肿瘤科 内科学 MEK抑制剂 化疗 甲状腺癌 威罗菲尼 癌症 MAPK/ERK通路 生物 细胞生物学 激酶 转移性黑色素瘤
作者
Rukiye Arıkan,Tuğba Akın Telli,Nazım Can Demircan,Tuğba Başoğlu,Özlem Ercelep,Beste Melek Atasoy,Salih Özgüven,Faysal Dane,Perran Fulden Yumuk
出处
期刊:Current Problems in Cancer [Elsevier]
卷期号:45 (2): 100668-100668 被引量:7
标识
DOI:10.1016/j.currproblcancer.2020.100668
摘要

Introduction: Anaplastic thyroid carcinoma (ATC) is a highly aggressive, undifferentiated rare tumor. Median overall survival is usually between 8 and10 months, with a 1-year survival rate of 20%. Conventional anthracycline based chemotherapy regimens demonstrate low response rates with short duration. Novel therapeutic agents including BRAF and MEK inhibitors based on the molecular landscape of ATC have been investigated. Case presentation: We herein report the rechallenge of a 52-year-old ATC patient with BRAF V600E mutation with dabrafenib plus trametinib. She presented with recurrent and progressive disease despite surgery, radiation therapy, 3 different chemotherapy regimens, and combination of dabrafenib-trametinib in different settings. She was rechallenged with dabrafenib-trametinib, and had a good response. Conclusion: To our knowledge, this is the first ATC case who responded to dabrafenib-trametinib rechallenge, reported in the literature. We want to emphasize that combination of dabrafenib and trametinib might be a good choice for resistant locoregional and metastatic ATC patients with BRAF V600E mutation, particularly in whom rapid clinical response is urgently needed. Moreover, rechallenge with this combination should be kept in mind in selected cases.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ppppp完成签到,获得积分10
2秒前
Darren发布了新的文献求助50
2秒前
闪闪元芹完成签到,获得积分10
5秒前
春江完成签到,获得积分10
7秒前
可爱的函函应助lql采纳,获得10
7秒前
我是老大应助yxy采纳,获得10
10秒前
12秒前
13秒前
Andy完成签到 ,获得积分10
16秒前
18秒前
18秒前
20秒前
ppppp发布了新的文献求助10
20秒前
24秒前
柯仇天发布了新的文献求助10
24秒前
鲸落发布了新的文献求助10
26秒前
31秒前
Master发布了新的文献求助20
35秒前
36秒前
juanjuan应助柯仇天采纳,获得10
36秒前
lige完成签到 ,获得积分10
37秒前
37秒前
38秒前
39秒前
王灿灿应助秋蚓采纳,获得50
40秒前
41秒前
42秒前
伊伊发布了新的文献求助30
44秒前
冷静沛白完成签到,获得积分10
45秒前
zoe发布了新的文献求助10
45秒前
背后书雪完成签到 ,获得积分10
46秒前
46秒前
小晞完成签到 ,获得积分10
47秒前
1huiqina发布了新的文献求助30
48秒前
49秒前
复杂大象完成签到,获得积分10
51秒前
独特觅翠完成签到 ,获得积分10
55秒前
57秒前
kkk驳回了iNk应助
59秒前
bkagyin应助zoe采纳,获得10
1分钟前
高分求助中
Sustainability in Tides Chemistry 2800
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Handbook of Qualitative Cross-Cultural Research Methods 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137638
求助须知:如何正确求助?哪些是违规求助? 2788565
关于积分的说明 7787590
捐赠科研通 2444902
什么是DOI,文献DOI怎么找? 1300139
科研通“疑难数据库(出版商)”最低求助积分说明 625814
版权声明 601023